Donor CAR-NK cells for thymoma or thymic carcinoma that came back
Tests CAR-NK cells in adults with hard-to-treat thymoma or thymic carcinoma.
Key facts
- Who runs it
- Beijing Biotech
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 36 people, planned
- Started
- 2 Mar 2026
- Expected to end
- 17 Apr 2028
- Type of study
- Interventional, 3 groups
- Treatments tested
- Cyclophosphamide
- Fludarabine
- EB-CAR30-NK
- EB-CAR5-NK
- EB-CARMSLN-NK
- Rimiducid (AP1903)
- Record updated
- 20 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with B2 thymoma or thymic carcinoma that came back or did not respond to treatment. Their tumor must carry CD30, CD5 or mesothelin.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- B2 thymoma or thymic carcinoma confirmed by tissue test. It cannot be removed by surgery, has spread, or has come back. Measurable disease per RECIST v1.1. ECOG performance status 0-1 (daily activity level); 0-2 may be allowed in the expansion part.
- Earlier treatment
- Disease came back or did not respond after at least 1 prior whole-body (systemic) therapy, including a platinum-based regimen for thymic carcinoma when appropriate. Or no standard treatment meant to remove all of the disease is available. No gene-modified cell therapy (such as CAR-T or CAR-NK) in the last 90 days.
- Biomarker or test result
- Tumor positive for at least one of CD30, CD5 or mesothelin, tested by a central laboratory.
Main reasons for not taking part
- Active cancer in the brain or spinal cord needing immediate treatment
- Uncontrolled infection, including active tuberculosis, hepatitis B or C, or known uncontrolled HIV
- Autoimmune disease needing more than 10 mg/day prednisone equivalent within 14 days of conditioning
- Serious heart disease, such as NYHA class III/IV heart failure or recent heart attack
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age 18 to 75 years at the time of consent
- Histologically confirmed B2 thymoma or thymic carcinoma that is unresectable, metastatic, or recurrent
- Relapsed or refractory after at least 1 prior systemic therapy (including a platinum-based regimen for thymic carcinoma when appropriate) or no standard curative option available
- Tumor antigen positivity for at least one of the following by central laboratory assessment: CD30, CD5, or mesothelin. Cohort assignment is based on the dominant target (pre-specified algorithm) and feasibility of manufacturing/availability
- Measurable disease per RECIST v1.1 (or evaluable disease if measurable disease is not feasible; to be specified)
- ECOG performance status 0-1 (0-2 may be permitted in expansion at investigator discretion)
- Adequate organ function: ANC ≥ 1.0 x 10\^9/L, platelets ≥ 75 x 10\^9/L, hemoglobin ≥ 8 g/dL (transfusions allowed), AST/ALT ≤ 3 x ULN (≤ 5 x ULN with liver involvement), total bilirubin ≤ 1.5 x ULN (except Gilbert's), creatinine clearance ≥ 50 mL/min
- Negative pregnancy test for participants of childbearing potential; agreement to use effective contraception
- Ability to understand and sign informed consent
Who cannot take part
- Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 90 days or unresolved ≥Grade 2 toxicity from prior cellular therapy
- Prior allogeneic hematopoietic stem cell transplant with active graft-versus-host disease or ongoing immunosuppression
- Concurrent participation in another interventional trial with an investigational anticancer agent within 21 days (washout required)
- Active central nervous system involvement by malignancy requiring immediate therapy
- Uncontrolled infection, including active tuberculosis, or uncontrolled hepatitis B or C infection; known uncontrolled HIV infection
- Clinically significant autoimmune disease requiring systemic immunosuppression (e.g., >10 mg/day prednisone equivalent) within 14 days of conditioning, except for stable endocrine replacement
- Any condition that, in the investigator's judgment, would interfere with safe participation or interpretation of results
- Significant cardiovascular disease (e.g., NYHA class III/IV heart failure, recent myocardial infarction), uncontrolled arrhythmia, or QTc prolongation felt to increase risk
- Pregnancy or breastfeeding
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma. Participants undergo centralized tumor antigen assessment (CD30, CD5, and mesothelin). Based on the dominant and clinically actionable antigen expression profile, each participant is assigned to one of three parallel cohorts (CD30-CAR-NK, CD5-CAR-NK, or mesothelin-CAR-NK). All cohorts use the same lymphodepleting conditioning regimen followed by CAR-NK infusion(s).
The 3 groups in the trial
- Cohort A: CD30-CAR-NKTreatment being tested
Lymphodepleting chemotherapy: cyclophosphamide + fludarabine (Days -5 to -3), followed by CAR-NK infusion on Day 0. A second infusion on Day 7 may be permitted at investigator discretion in Phase 2 if no ≥Grade 3 treatment-related toxicity is observed and product is available.
Treatment: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK, and Rimiducid (AP1903)
- Cohort B: CD5-CAR-NKTreatment being tested
Lymphodepleting chemotherapy: cyclophosphamide + fludarabine (Days -5 to -3), followed by CAR-NK infusion on Day 0. A second infusion on Day 7 may be permitted at investigator discretion in Phase 2 if no ≥Grade 3 treatment-related toxicity is observed and product is available.
Treatment: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK, and Rimiducid (AP1903)
- Cohort C: Mesothelin-CAR-NKTreatment being tested
Lymphodepleting chemotherapy: cyclophosphamide + fludarabine (Days -5 to -3), followed by CAR-NK infusion on Day 0. A second infusion on Day 7 may be permitted at investigator discretion in Phase 2 if no ≥Grade 3 treatment-related toxicity is observed and product is available.
Treatment: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK, and Rimiducid (AP1903)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, Open-Label, Target-Selected Study of Allogeneic CAR-NK Cells Directed to CD30, CD5, or Mesothelin in Patients With Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
- Plain-language title
- Donor CAR-NK cells for thymoma or thymic carcinoma that came backGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07598955, who can take part
- Record updated
- 20 May 2026